Analysts: BioCryst Phase I Results are Positive and 3 More Research Notes to Leaf Through

BioCryst (NASDAQ:BCRX): JMP Securities increased its target on BioCryst after the company reported the Phase I results for its oral kallekrien inhibitor, BCX4161, which the firm sees as solid and positive. It keeps an Outperform rating on the stock and raised its price target on shares to $5 from $3.


Baker Hughes (NYSE:BHI): Macquarie believes Baker Hughes’s margins bottomed out in the second quarter and are poised for multi-quarter margin expansion. As a result, the firm raised its price target to $54 from $48 and upgrades its rating from Netural to Outperform.


Zions Bancorp (NASDAQ:ZION): DA Davidson downgraded Zions to Neutral from Buy and lowered its estimates to better reflect the increased costs from system upgrades and loan portfolio repricing. The price target has also been lowered, to $32 from $37.


Hercules Offshore (NASDAQ:HERO): Global Hunter says that the Hercules Offshore well blowout was natural gas with minimal pollution, and the company has insurance that will cover up to $200 million in damages, therefore limiting any kickback.


Investing Insights: Can Celgene Continue Its Impressive Growth?